The trajectory of companies tied to the drug's legacy presents a complex investment scenario . While the initial surge generated substantial gains, generic copies have significantly diminished revenue. Investing in associated pharmaceutical firms now requires a careful assessment of patent protection , evolving medical trends , and the potential fo